B. Metzler Seel. Sohn & Co. Ag Intra Cellular Therapies, Inc. Transaction History

B. Metzler Seel. Sohn & Co. Ag

$10 Billion
Q3 2024

A detailed history of B. Metzler Seel. Sohn & Co. Ag transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, B. Metzler Seel. Sohn & Co. Ag holds 33,291 shares of ITCI stock, worth $2.77 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

33,291

Previous 30,341 9.72%

Holding current value

$2.77 Million

Previous $2.08 Million 17.13%

% of portfolio

0.02%

Previous 0.02%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	BUY	$67.99 - $80.84 $200,570 - $238,478	2,950 Added 9.72%	33,291 $2.43 Million
Q1 2024 May 15, 2024	BUY	$64.37 - $75.65 $278,979 - $327,867	4,334 Added 16.66%	30,341 $2.1 Million
Q4 2023 Feb 13, 2024	BUY	$46.37 - $73.65 $17,342 - $27,545	374 Added 1.46%	26,007 $1.86 Million
Q3 2023 Nov 13, 2023	SELL	$52.09 - $64.1 $1.17 Million - $1.44 Million	-22,389 Reduced 46.62%	25,633 $1.34 Million
Q2 2023 Aug 11, 2023	BUY	$54.67 - $66.44 $1.12 Million - $1.36 Million	20,412 Added 73.93%	48,022 $3.04 Million
Q1 2023 May 10, 2023	SELL	$43.8 - $56.99 $132,013 - $171,767	-3,014 Reduced 9.84%	27,610 $1.5 Million
Q4 2022 Feb 13, 2023	BUY	$44.07 - $54.45 $94,177 - $116,359	2,137 Added 7.5%	30,624 $1.62 Million
Q3 2022 Nov 14, 2022	BUY	$42.7 - $59.99 $20,410 - $28,675	478 Added 1.71%	28,487 $1.33 Million
Q2 2022 Aug 12, 2022	SELL	$43.0 - $65.64 $319,146 - $487,180	-7,422 Reduced 20.95%	28,009 $1.6 Million
Q1 2022 May 10, 2022	BUY	$38.74 - $62.09 $139,464 - $223,524	3,600 Added 11.31%	35,431 $2.17 Million
Q4 2021 Feb 11, 2022	BUY	$35.2 - $53.42 $1.12 Million - $1.7 Million	31,831 New	31,831 $1.66 Million

Others Institutions Holding ITCI

# of Institutions

378

Shares Held

84.7M

Call Options Held

319K

Put Options Held

143K

View Full List

About Intra-Cellular Therapies, Inc.

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $7.85B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

More about ITCI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of B. Metzler Seel. Sohn & Co. Ag, based on Form 13F filings with the SEC.

News

Stay updated on B. Metzler Seel. Sohn & Co. Ag with notifications on news.

Account

B. Metzler Seel. Sohn & Co. Ag Intra Cellular Therapies, Inc. Transaction History